미국의 멀티오믹스 시장 규모, 점유율, 동향 분석 보고서 : 제품 및 서비스별, 유형별, 플랫폼별, 용도별, 최종 용도별, 부문별 예측(2025-2033년)

U.S. Multiomics Market Summary

The U.S. multiomics market size was estimated at USD 1.18 billion in 2024 and is projected to reach USD 4.36 billion by 2033, growing at a CAGR of 15.58% from 2025 to 2033. This significant growth is driven by increasing demand for personalized medicine, the integration of artificial intelligence and machine learning in biological data interpretation, and the growing need for comprehensive disease profiling. Moreover, rising investments in research and development by both the government and private sectors and expanding applications in drug discovery, diagnostics, and precision healthcare are expected to propel market growth further over the forecast period.

Technological Innovations

The rapid pace of technological innovation across omics platforms and analytical tools is the key driver in the U.S. multiomics industry. Breakthroughs in high-throughput sequencing technologies, such as next-generation sequencing (NGS), have dramatically increased the speed and depth of genomic and transcriptomic data generation while reducing the cost per sample. Similarly, advancements in mass spectrometry, chromatography, and imaging technologies have significantly improved the resolution and sensitivity of proteomics and metabolomics studies. These innovations enable researchers to obtain a more detailed and accurate view of complex biological processes, essential for applications in disease research, drug discovery, and precision diagnostics.

The evolution of powerful computational tools, cloud-based platforms, and AI-driven analytics has revolutionized how multiomics data is processed, integrated, and interpreted. These technologies allow for the seamless analysis of large-scale, multi-layered datasets, reducing bottlenecks in data handling and accelerating insights. As a result, multiomics workflows are becoming more automated, scalable, and cost-effective, making them increasingly accessible to large pharmaceutical companies and smaller biotech firms, academic institutions, and clinical laboratories. The convergence of these technological advancements is not only expanding the application of multiomics across new disease areas. Still, it is also helping to democratize access to multiomics research, thereby accelerating the market's growth in the U.S.

U.S. Multiomics Market Report Segmentation

This report forecasts revenue growth at the country level and provides an analysis of the latest trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the U.S. multiomics market report based on product & service, type, platform, application, and end use:

• Product & Service Outlook (Revenue, USD Million, 2021 - 2033)
• Products
  • Instruments
  • Consumables
  • Software
• Services
• Type Outlook (Revenue, USD Million, 2021 - 2033)
• Single-cell Multiomics
• Bulk Multiomics
• Platform Outlook (Revenue, USD Million, 2021 - 2033)
• Genomics
• Transcriptomics
• Proteomics
• Metabolomics
• Integrated Omics Platforms
• Application Outlook (Revenue, USD Million, 2021 - 2033)
• Cell Biology
• Oncology
• Neurology
• Immunology
• End Use Outlook (Revenue, USD Million, 2021 - 2033)
• Academic and Research Institutes
• Pharmaceutical & Biotechnology Companies
• Others

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation and Scope
• 1.2. Market Definitions
  • 1.2.1. Product & Service
  • 1.2.2. Type
  • 1.2.3. Platform
  • 1.2.4. Application
  • 1.2.5. End Use
• 1.3. Information analysis
• 1.4. Market formulation & data visualization
• 1.5. Data validation & publishing
• 1.6. Information Procurement
  • 1.6.1. Primary Research
• 1.7. Information or Data Analysis
• 1.8. Market Formulation & Validation
• 1.9. Market Model
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Snapshot
• 2.3. Competitive Landscape Snapshot

Chapter 3. Market Variables, Trends, & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent Market Outlook
  • 3.1.2. Related/Ancillary Market Outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
    • 3.2.1.1. Technological Innovation
    • 3.2.1.2. Advancements in precision medicine
  • 3.2.2. Market Restraint Analysis
    • 3.2.2.1. Data integration and analytical complexity
    • 3.2.2.2. High cost of multiomics technologies and workflows
• 3.3. Industry Analysis Tools
  • 3.3.1. Porter's Five Forces Analysis
  • 3.3.2. PESTEL Analysis

Chapter 4. U.S. Multiomics Market: Product & Service Business Analysis

• 4.1. Segment Dashboard
• 4.2. U.S. Multiomics Market Product & Service Movement Analysis
• 4.3. U.S. Multiomics Market Size & Trend Analysis, by Product & Service, 2021 to 2033 (USD Million)
• 4.4. Product
  • 4.4.1. Product Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.4.2. Instruments
    • 4.4.2.1. Instruments Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.4.3. Consumables
    • 4.4.3.1. Consumables Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.4.4. Software
    • 4.4.4.1. Software Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 4.5. Services
  • 4.5.1. Services Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 5. U.S. Multiomics Market: Type Business Analysis

• 5.1. Segment Dashboard
• 5.2. U.S. Multiomics Market Type Movement Analysis
• 5.3. U.S. Multiomics Market Size & Trend Analysis, by Type, 2021 to 2033 (USD Million)
• 5.4. Single-cell Multiomics
  • 5.4.1. Single-cell Multiomics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.5. Bulk Multiomics
  • 5.5.1. Bulk. Multiomics Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 6. U.S. Multiomics Market: Platform Business Analysis

• 6.1. Segment Dashboard
• 6.2. U.S. Multiomics Market Platform Movement Analysis
• 6.3. U.S. Multiomics Market Size & Trend Analysis, by Platform, 2021 to 2033 (USD Million)
• 6.4. Genomics
  • 6.4.1. Genomics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.5. Transcriptomics
  • 6.5.1. Transcriptomics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.6. Proteomics
  • 6.6.1. Proteomics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.7. Metabolomics
  • 6.7.1. Metabolomics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.8. Integrated Omics Platforms
  • 6.8.1. Integrated Omics Platforms Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 7. U.S. Multiomics Market: Application Business Analysis

• 7.1. Segment Dashboard
• 7.2. U.S. Multiomics Market Application Movement Analysis
• 7.3. U.S. Multiomics Market Size & Trend Analysis, by Application, 2021 to 2033 (USD Million)
• 7.4. Cell Biology
  • 7.4.1. Cell Biology Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 7.5. Oncology
  • 7.5.1. Oncology Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 7.6. Neurology
  • 7.6.1. Neurology Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 7.7. Immunology
  • 7.7.1. Immunology Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 8. U.S. Multiomics Market: End Use Business Analysis

• 8.1. Segment Dashboard
• 8.2. U.S. Multiomics Market End Use Movement Analysis
• 8.3. U.S. Multiomics Market Size & Trend Analysis, by End Use, 2021 to 2033 (USD Million)
• 8.4. Academic and Research Institutes
  • 8.4.1. Academic and Research Institutes Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 8.5. Pharmaceutical & Biotechnology Companies
  • 8.5.1. Pharmaceutical & Biotechnology Companies Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 8.6. Others
  • 8.6.1. Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 9. Competitive Landscape

• 9.1. Participant Categorization
• 9.2. Strategy Mapping
• 9.3. Company Market Position Analysis, 2024
• 9.4. Participant's Overview
  • 9.4.1. BD
    • 9.4.1.1. Overview
    • 9.4.1.2. Financial Performance
    • 9.4.1.3. Product Benchmarking
    • 9.4.1.4. Strategic Initiatives
  • 9.4.2. Thermo Fisher Scientific Inc.
    • 9.4.2.1. Overview
    • 9.4.2.2. Financial Performance
    • 9.4.2.3. Product Benchmarking
    • 9.4.2.4. Strategic Initiatives
  • 9.4.3. Illumina, Inc
    • 9.4.3.1. Overview
    • 9.4.3.2. Financial Performance
    • 9.4.3.3. Product Benchmarking
    • 9.4.3.4. Strategic Initiatives
  • 9.4.4. Danaher (Beckman Coulter)
    • 9.4.4.1. Overview
    • 9.4.4.2. Financial Performance
    • 9.4.4.3. Product Benchmarking
    • 9.4.4.4. Strategic Initiatives
  • 9.4.5. PerkinElmer Inc.
    • 9.4.5.1. Overview
    • 9.4.5.2. Financial Performance
    • 9.4.5.3. Product Benchmarking
    • 9.4.5.4. Strategic Initiatives
  • 9.4.6. Shimadzu Corporation
    • 9.4.6.1. Overview
    • 9.4.6.2. Financial Performance
    • 9.4.6.3. Product Benchmarking
    • 9.4.6.4. Strategic Initiatives
  • 9.4.7. Bruker
    • 9.4.7.1. Overview
    • 9.4.7.2. Financial Performance
    • 9.4.7.3. Product Benchmarking
    • 9.4.7.4. Strategic Initiatives
  • 9.4.8. QIAGEN
    • 9.4.8.1. Overview
    • 9.4.8.2. Financial Performance
    • 9.4.8.3. Product Benchmarking
    • 9.4.8.4. Strategic Initiatives
  • 9.4.9. Agilent Technologies, Inc.
    • 9.4.9.1. Overview
    • 9.4.9.2. Financial Performance
    • 9.4.9.3. Product Benchmarking
    • 9.4.9.4. Strategic Initiatives
  • 9.4.10. BGI Genomics
    • 9.4.10.1. Overview
    • 9.4.10.2. Financial Performance
    • 9.4.10.3. Product Benchmarking
    • 9.4.10.4. Strategic Initiatives